Radspherin
Radspherin is an experimental drug designed for the treatment of metastatic cancers in body cavities. The drug is in its pre-clinical development phase. Clinical testing of Radspherin for treatment of peritoneal carcinomatosis originating from ovarian cancer is planned to start in 2018. Peritoneal carcinomatosis is a serious complication of gastrointestinal and gynecological malignancies with limited treatment options.
Radspherin consists of alpha particle emitting Radium-224-labeled calcium carbonate microparticles. The microparticles prevent Radium-244 from leaking out of the body cavity where it provides highly targeted radiation of cancer metastasis [1]. Intraperitoneal therapy with radioactive particles have long been investigated. Beta-emitting particles was used in cancer treatment in the 1980s. The treatment was shown to be effective, but resulted in late bowel complications [2]. Short range, high-energy alpha particle radiation is assumed to be more efficient and prevents irradiation of deeper regions of sensitive abdominal organs, such as the small intestine.
Radspherin shows consistent anticancer effect in mice with intraperitoneal ovarian cancer [3][4]. It was invented by Roy Hartvig Larsen and Sara Westrøm, and the patent is assigned to OncoInvent [5]. Radspherin is being developed by the same researchers that successfully developed Xofigo using an α-emitting radioisotope to treat bone metastasis from prostate cancer.
External links[edit]
References[edit]
- ↑ Westrøm, Sara; Malenge, Marion; Jorstad, Ida Sofie; Napoli, Elisa; Bruland, Øyvind S.; Bønsdorff, Tina B.; Larsen, Roy H. (30 May 2018). "Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice". Journal of Labelled Compounds and Radiopharmaceuticals. 61 (6): 472–486. doi:10.1002/jlcr.3610. PMID 29380410.
- ↑ Vergote, IB; Vergote-De Vos, LN; Abeler, VM; Aas, M; Lindegaard, MW; Kjørstad, KE; Tropé, CG (1 February 1992). "Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer". Cancer. 69 (3): 741–9. PMID 1730124.
- ↑ Westrøm, Sara; Bønsdorff, Tina B.; Bruland, Øyvind S.; Larsen, Roy H. (2018-04-01). "Therapeutic Effect of α-Emitting 224 Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer". Translational Oncology. 11 (2): 259–267. doi:10.1016/j.tranon.2017.12.011. ISSN 1936-5233. PMID 29413758.
- ↑ "Annual Congress of the European Association of Nuclear Medicine" (PDF). European Association of Nuclear Medicine. p. 65.
- ↑ US Granted US9539346, Roy Hartvig Larsen & Sara WESTRØM, "Radiotherapeutic particles and suspensions", published Jan 10, 2017, assigned to Oncoinvent As
This article "Radspherin" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Radspherin. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
